# A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

> **NCT05071664** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 91 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Golimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05071664
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-25
- **Primary completion:** 2024-05-14
- **Final completion:** 2024-08-06
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05071664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05071664, "A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05071664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*